This recommendation is an update to the 2020 ASCO guideline on optimal adjuvant chemotherapy and targeted therapy for the ...
The CAR T-cell therapy ADI-270 received fast track designation from the FDA for pretreated advanced clear cell renal cell ...
Quality-of-life scores for the patients at week 24, measured by the Functional Assessment of Cancer Therapy-Lung (FACT-L), ...
Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard ...
Oncology nurses play a critical role in identifying and managing rare audiovestibular complications associated with immune ...
An oncology nurse's experience with her mother's cancer and her own BRCA2 diagnosis shapes her approach to patient care.
This analysis of patients with previously treated advanced clear cell renal cell carcinoma treated with belzutifan is the ...
The updated risk evaluation and mitigation strategies for autologous CAR T-cell therapy removed requirements for training and ...
A durvalumab-based combination followed by an olaparib-based maintenance therapy improved progression-free survival in newly ...
Final results of the ARMANI trial demonstrated that switch maintenance therapy with ramucirumab plus paclitaxel improved survival in advanced HER2-negative gastric or gastroesophageal junction cancer.
With several options available for the second-line treatment of HR-positive, HER2-negative mBC, an expert emphasized the ...